RiverPark Advisors LLC Sells 5,186 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

RiverPark Advisors LLC trimmed its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 27.5% in the third quarter, according to its most recent filing with the SEC. The firm owned 13,642 shares of the medical technology company’s stock after selling 5,186 shares during the period. RiverPark Advisors LLC’s holdings in Alphatec were worth $76,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Royce & Associates LP lifted its holdings in shares of Alphatec by 15.9% during the 3rd quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company’s stock worth $6,740,000 after acquiring an additional 165,954 shares during the period. Zions Bancorporation N.A. lifted its holdings in shares of Alphatec by 108.2% during the 3rd quarter. Zions Bancorporation N.A. now owns 173,180 shares of the medical technology company’s stock worth $963,000 after acquiring an additional 89,992 shares during the period. GSA Capital Partners LLP bought a new position in shares of Alphatec during the 3rd quarter worth about $431,000. Entropy Technologies LP lifted its holdings in shares of Alphatec by 14.9% during the 3rd quarter. Entropy Technologies LP now owns 21,623 shares of the medical technology company’s stock worth $120,000 after acquiring an additional 2,800 shares during the period. Finally, Atria Investments Inc lifted its holdings in shares of Alphatec by 8.0% during the 3rd quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock worth $109,000 after acquiring an additional 1,460 shares during the period. 66.35% of the stock is owned by institutional investors.

Alphatec Stock Performance

Shares of NASDAQ ATEC opened at $8.23 on Friday. The firm has a 50 day moving average price of $6.30 and a 200 day moving average price of $8.36. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $17.34.

Insider Activity at Alphatec

In other news, Director David M. Demski acquired 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The stock was purchased at an average price of $5.67 per share, for a total transaction of $283,500.00. Following the completion of the acquisition, the director now owns 288,441 shares in the company, valued at $1,635,460.47. This trade represents a 20.97 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 22.80% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on ATEC shares. Lake Street Capital cut their price target on shares of Alphatec from $32.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $13.00 target price on shares of Alphatec in a research note on Thursday, October 31st. Stifel Nicolaus dropped their target price on shares of Alphatec from $19.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Piper Sandler dropped their target price on shares of Alphatec from $17.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, August 1st. Finally, Morgan Stanley downgraded shares of Alphatec from an “overweight” rating to an “equal weight” rating in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $17.00.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.